Medications for Parkinson's disease

Neurologist. 2007 Nov;13(6):387-8. doi: 10.1097/NRL.0b013e318158e47d.
No abstract available

Publication types

  • Patient Education Handout

MeSH terms

  • Amantadine / adverse effects
  • Amantadine / pharmacology
  • Amantadine / therapeutic use
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacology*
  • Antiparkinson Agents / therapeutic use
  • Brain / drug effects
  • Brain / metabolism
  • Brain / physiopathology
  • Cholinergic Antagonists / adverse effects
  • Cholinergic Antagonists / pharmacology
  • Cholinergic Antagonists / therapeutic use
  • Dopamine / metabolism
  • Dopamine Agents / adverse effects
  • Dopamine Agents / pharmacology*
  • Dopamine Agents / therapeutic use
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology
  • Receptors, Dopamine / drug effects
  • Receptors, Dopamine / metabolism

Substances

  • Antiparkinson Agents
  • Cholinergic Antagonists
  • Dopamine Agents
  • Enzyme Inhibitors
  • Receptors, Dopamine
  • Amantadine
  • Dopamine